{
    "nctId": "NCT05149014",
    "briefTitle": "Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer",
    "officialTitle": "Real-world Study on Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with Metastatic or Unresectable HER2-positive Breast Cancer: a French Ambispective Multicentre 2 Year-follow-up Cohort Study",
    "overallStatus": "COMPLETED",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 306,
    "primaryOutcomeMeasure": "Percentage of patients with at least one Trastuzumab deruxtecan related Adverse Drug Reaction of interest",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female adult patient (age \u2265 18 years);\n* Unresectable or metastatic HER2+ breast cancer, previously treated with at least 2 lines of anti-HER2, and:\n\n  * previously treated by compassionate trastuzumab deruxtecan (ATU group), or\n  * previously treated or planned to be treated by trastuzumab deruxtecan (Enhertu\u00ae), upon the investigator's decision (Post-Marketing authorization group);\n* Patient who expresses non-opposition to participate in the study, or deceased patient who did not express his/her opposition to the use of his/her personal data while alive.\n\nExclusion Criteria:\n\n- Previous participation in an interventional clinical trial with trastuzumab deruxtecan",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}